We are live on
!
Find out more
FGP
Foyston, Gordon, & Payne Portfolio holdings
AUM
$434M
1-Year Est. Return
9.09%
This Fund
S&P 500
This Quarter
Est. Return
+8.84%
1 Year Est. Return
+9.09%
3 Year Est. Return
+56.86%
5 Year Est. Return
+84.63%
10 Year Est. Return
+238.52%
AUM
$806M
AUM Growth
+$39.4M
(+5.1%)
Cap. Flow
-$29.8M
Cap. Flow
% of AUM
-3.69%
Top 10 Holdings %
Top 10 Hldgs %
34.27%
Holding
91
New
6
Increased
24
Reduced
39
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Baxter International
BAX
|
+$17.3M |
| 2 |
Abercrombie & Fitch
ANF
|
+$11.4M |
| 3 |
Conagra Brands
CAG
|
+$10.6M |
| 4 |
Teradata
TDC
|
+$7.16M |
| 5 |
Stanley Black & Decker
SWK
|
+$6.99M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cardinal Health
CAH
|
+$24.9M |
| 2 |
Devon Energy
DVN
|
+$9.55M |
| 3 |
Oracle
ORCL
|
+$9.36M |
| 4 |
Ryder
R
|
+$8.92M |
| 5 |
Microsoft
MSFT
|
+$8.45M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.04% |
| 2 | Technology | 15.29% |
| 3 | Financials | 14.55% |
| 4 | Energy | 11.39% |
| 5 | Consumer Staples | 10.82% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Procter & Gamble
PG
$340B
| $860K | 0.11% |
10,563
| – | – |
|
77
Becton Dickinson
BDX
$46.4B
| $696K | 0.09% |
6,458
| – | – |
|
78
Novartis
NVS
$302B
| $693K | 0.09% |
9,619
| – | – |
|
79
AbbVie
ABBV
$465B
| $664K | 0.08% |
12,570
| – | – |
|
80
RTX Corp
RTX
$290B
| $590K | 0.07% |
8,239
| – | – |
|
81
IBM
IBM
$213B
| $586K | 0.07% |
3,270
| – | – |
|
82
iShares Core S&P 500 ETF
IVV
$858B
| $576K | 0.07% |
3,100
| – | – |
|
83
Abbott
ABT
$188B
| $482K | 0.06% |
12,570
| – | – |
|
84
US Bancorp
USB
$97.9B
| $386K | 0.05% |
9,553
| – | – |
|
85
Wells Fargo
WFC
$254B
| $337K | 0.04% |
7,421
| – | – |
|
|
ACET
86
DELISTED
Aceto Corp
ACET
| $296K | 0.04% |
11,851
| – | – |
|
87
JPMorgan Chase
JPM
$916B
| $261K | 0.03% |
4,471
| – | – |
|
|
CMA
88
DELISTED
Comerica
CMA
| $229K | 0.03% |
+4,820
| New | +$212K |
|
89
Pfizer
PFE
$143B
| $214K | 0.03% |
7,371
| – | – |
|
90
Unilever
UL
$142B
| – | – |
-82,206
| Closed | -$3.57M |
|
|
RFP
91
DELISTED
Resolute Forest Products Inc.
RFP
| – | – |
-251,344
| Closed | -$3.45M |
|
Similar funds
HCM
GS
IA
PAMS
SSWG
JWM
GDS
GPP
Foyston, Gordon, & Payne's Q4 2013 Portfolio in Review
As of Q4 2013, Foyston, Gordon, & Payne held 91 positions worth $806M, up 5.1% from $766M the previous quarter. Its ten largest holdings account for 34% of the portfolio.
Foyston, Gordon, & Payne withdrew a net $29.8M in Q4 2013, closing 2 positions and reducing 39 holdings. Its most notable exit was Unilever, an estimated $3.57M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 20% a quarter earlier, followed by Technology and Financials.
Against the trend, Foyston, Gordon, & Payne opened a new position in Baxter International worth $18M.
- Foyston, Gordon, & Payne's largest Q4 2013 buy was Baxter International: 476,710 shares worth $18M.
- Foyston, Gordon, & Payne added most to Conagra Brands in Q4 2013, an estimated $10.6M increase.
- Foyston, Gordon, & Payne's biggest Q4 2013 reduction was Cardinal Health, cutting an estimated $24.9M.
- Foyston, Gordon, & Payne fully exited Unilever in Q4 2013, selling an estimated $3.57M.
- Foyston, Gordon, & Payne's ten largest holdings make up 34% of its $806M portfolio in Q4 2013.
- Foyston, Gordon, & Payne opened 6 new positions and closed 2 in Q4 2013.
- Foyston, Gordon, & Payne's portfolio value rose 5.1% quarter-over-quarter to $806M.
Based on Foyston, Gordon, & Payne's 13F filing for Q4 2013, filed 13 Feb 2014.